Cargando…

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness. APPROA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Indira Chandran, Vineesh, Wernberg, Charlotte Wilhelmina, Lauridsen, Mette Munk, Skytthe, Maria Kløjgaard, Bendixen, Sofie Marchsteiner, Larsen, Frederik Tibert, Hansen, Camilla Dalby, Grønkjær, Lea Ladegaard, Siersbæk, Majken Storm, Caterino, Tina Di, Detlefsen, Sönke, Møller, Holger Jon, Grøntved, Lars, Ravnskjaer, Kim, Moestrup, Søren Kragh, Thiele, Maja Sofie, Krag, Aleksander, Graversen, Jonas Heilskov
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Steatohepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869959/ https://www.ncbi.nlm.nih.gov/pubmed/35712786 http://dx.doi.org/10.1002/hep.32620

Ejemplares similares

Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity
por: Larsen, Frederik T., et al.
Publicado: (2022)

Drug Trafficking into Macrophages via the Endocytotic Receptor CD163
por: Graversen, Jonas Heilskov, et al.
Publicado: (2015)

Targeting of CD163(+) Macrophages in Inflammatory and Malignant Diseases
por: Skytthe, Maria K., et al.
Publicado: (2020)

Are Nonalcoholic Fatty Liver Disease and Bone Mineral Density Associated? — A Cross‐Sectional Study Using Liver Biopsy and Dual‐Energy X‐Ray Absorptiometry
por: Hansen, Stinus Gadegaard, et al.
Publicado: (2023)

Reply to Letter to the Editor: Neurocognitive impairment in obesity and liver disease—An unsolved mystery
por: Wernberg, Charlotte Wilhelmina, et al.
Publicado: (2023)

The prevalence and risk factors for cognitive impairment in obesity and NAFLD
por: Wernberg, Charlotte W., et al.
Publicado: (2023)

Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review
por: Grønkjær, Lea Ladegaard, et al.
Publicado: (2021)

Reply to: “Comment on “Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review””
por: Grønkjær, Lea Ladegaard, et al.
Publicado: (2021)

The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients
por: Wernberg, Charlotte W., et al.
Publicado: (2021)

Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease—Current Knowledge, Mechanisms and Perspectives
por: Kjærgaard, Kristoffer, et al.
Publicado: (2021)

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis
por: Yan, Tingting, et al.
Publicado: (2023)

Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
por: Ren, Zhewen, et al.
Publicado: (2023)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
por: Deprince, Audrey, et al.
Publicado: (2023)

RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease
por: Afonso, Marta B., et al.
Publicado: (2023)

Myeloid p38 activation maintains macrophage–liver crosstalk and BAT thermogenesis through IL‐12–FGF21 axis
por: Crespo, María, et al.
Publicado: (2023)

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice
por: Kim, Kyung Eun, et al.
Publicado: (2023)

Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
por: van Kleef, Laurens A., et al.
Publicado: (2023)

Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosis
por: Wu, Xiaoqin, et al.
Publicado: (2023)

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression
por: Juárez‐Fernández, María, et al.
Publicado: (2023)

The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories
por: Lazarus, Jeffrey V., et al.
Publicado: (2023)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent
por: Goikoetxea-Usandizaga, Naroa, et al.
Publicado: (2023)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
por: Li, Jiahui, et al.
Publicado: (2023)

Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study
por: van Kleef, Laurens A., et al.
Publicado: (2023)

Hepatic mitochondrial NAD(+) transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis
por: Cheng, Lili, et al.
Publicado: (2023)

Knowledge needs in patients with Liver Disease: a qualitative study
por: Jacobsen, Birgitte Gade, et al.
Publicado: (2023)

Transcriptional regulation of Hepatic Stellate Cell activation in NASH
por: Marcher, Ann-Britt, et al.
Publicado: (2019)

Transcriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury
por: Terkelsen, Mike K., et al.
Publicado: (2020)

Mental Health, Quality of Life, and Stigmatization in Danish Patients with Liver Disease
por: Østberg, Nadja, et al.
Publicado: (2023)

Specific targeting of CD163(+) TAMs mobilizes inflammatory monocytes and promotes T cell–mediated tumor regression
por: Etzerodt, Anders, et al.
Publicado: (2019)

Periodontal disease and liver cirrhosis: A systematic review
por: Grønkjær, Lea Ladegaard
Publicado: (2015)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance
por: Lee, Hui-Young, et al.
Publicado: (2011)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Role of Patatin-Like Phospholipase Domain-Containing 3 on Lipid-Induced Hepatic Steatosis and Insulin Resistance in Rats
por: Kumashiro, Naoki, et al.
Publicado: (2013)

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
por: Harley, Isaac TW, et al.
Publicado: (2014)

The small molecule, genistein, increases hepcidin expression in human hepatocytes
por: Zhen, Aileen W, et al.
Publicado: (2013)

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
por: Loomba, Rohit, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9d7thoeo6dsk2eaa9ne70f9hqg